Fulcrum Therapeutics, Inc. (FULC) vs InflaRx N.V. (IFRX)

Fulcrum Therapeutics, Inc. and InflaRx N.V. are both Biotechnology companies. Fulcrum Therapeutics, Inc. and InflaRx N.V. are of similar size ($288.8M and $284.4M). Fulcrum Therapeutics, Inc. grew revenue faster over the last twelve months: 1,939.8% against −83.4%. Across the 12 metrics below, Fulcrum Therapeutics, Inc. leads on 8 and InflaRx N.V. on 4.

Valuation

Metric FULC IFRX Biotechnology median
P/E n/m n/m 7.88
P/S 3.46 7,267.48 11.47
P/B 0.92 1.31 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.35 n/m 0.74
EV/Sales (0.41) 1,130.56 10.73
Earnings yield (32.35%) (30.69%) (28.84%)
Free cash flow yield (23.03%) (12.29%) (23.03%)

Profitability

Metric FULC IFRX Biotechnology median
Gross margin 100.00% (26,762.42%) 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (32.38%) (38.71%) (57.72%)
Return on assets (30.75%) (32.75%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric FULC IFRX Biotechnology median
Revenue growth (TTM) 1,939.80% (83.39%) 5.64%
EPS growth (last fiscal year) (637.50%) 9.41% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FULC IFRX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 31.35 8.22 4.73
Net debt to EBITDA 4.23 0.97 0.96

Dividend

Metric FULC IFRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric FULC IFRX Biotechnology median
Market cap 288.79m 284.42m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack